Lilly's $2.8B Psychedelic Deal Just Closed — Track the $1B Still on the Table

Eli Lilly announced this morning that it has closed its acquisition of AtaiBeckley: $6.75 a share in cash, worth roughly $2.8 billion, with up to another $1 billion of milestone payments on top. By size it is the largest buyout in the history of psychedelic medicine, and it gives Lilly an intranasal psychedelic — BPL-003, a synthetic form of 5-MeO-DMT — pointed at treatment-resistant depression.

That is the headline. It is also the part that no longer matters. The part that matters is the part that has not happened yet, because there the reader can check tonight whether this deal is a rounding error for Lilly or a live bet worth following.

The two buckets of the price

Press coverage uses "$2.8 billion" and "up to $3.8 billion" almost interchangeably, and they are not the same thing. The deal splits into two distinct pieces:

• Upfront: $6.75 per share in cash, an aggregate equity value of about $2.8 billion, and roughly a 40% premium to AtaiBeckley's 30-day volume-weighted average trading price as of July 15.
• Contingent value rights (CVRs): up to $2.50 more per share, about $1 billion in total, paid only if specific milestones land.

A CVR is a lottery ticket printed by the seller's own contract. You can read it before you buy anything. Here is the payoff schedule, dollar for dollar:

Trigger	Pays
VLS-01 Phase 3 trial initiated within 4 years of closing	$1.00/share
BPL-003 U.S. approval and DEA rescheduling within 5 years	$0.50/share
VLS-01 U.S. approval and DEA rescheduling within 7 years	$1.00/share

This table is the article's real deliverable, because it converts a rumor into a checklist. The two big payments hinge on VLS-01, the secondary asset, not on BPL-003, the one the press release leads with. And the milestone dates reach four and seven years out — meaning most of the "up to $3.8 billion" number is far-dated and uncertain, not money that lands this quarter.

What Lilly actually bought

Step one opens the pipeline page. The lead program, BPL-003, is a mebufotenin benzoate nasal spray — a fast-acting neuroplastogen meant to rebuild synaptic connections rather than rebalance neurotransmitter levels, delivered in a supervised in-clinic visit of about two hours. It already carries FDA Breakthrough Therapy Designation, and Phase 3 work has started across two pivotal studies. AtaiBeckley's own results: a Phase 2a cohort of just 12 patients showed roughly two-thirds reaching an antidepressant response by day two, with most holding it through week twelve, and a November 2025 Phase 2b topline came back positive.

Round out the roster with the two supporting assets: VLS-01, a DMT film for treatment-resistant depression, mid-study in Phase 2b with a Phase 3 for major depressive disorder planned; and EMP-01, an (R)-MDMA compound for social anxiety disorder, in Phase 2.

None of this is a curiosity for Lilly because the market has already been proven, by someone else, at scale. Johnson & Johnson's esketamine spray Spravato has grown to roughly $1.7 billion a year by 2026, and its certified dosing sites jumped from about 2,800 in 2024 to more than 7,000 in 2026. BPL-003 is Lilly's attempt to run the same play with a different molecule in the same treatment-resistant depression niche.

Two readings, one selector

The bullish read: Lilly is buying a challenger to a franchise J&J has shown is worth a billion dollars a year, and at $2.8 billion upfront it is cheap insurance for a company that has been writing checks all year — Centessa for roughly $7.8 billion. If Phase 3 hits and the DEA reschedules, the CVR pays and Lilly owns a real franchise.

The bearish read is where the discipline lives. The flashy "durable relief" numbers came out of a 12-patient cohort; a positive topline is not proof, and Phase 3 is where expensive molecules go to die. Just as important, BPL-003 is administered in a supervised clinic (patients were discharged roughly 100 minutes post-dose) and needs federal schedule rescheduling to be sold. That is exactly the scaling friction Spravato's own rollout showed: a drug that needs a chair, a nurse, and a controlled-substance pipeline grows revenue slower than a pill.

The data window that separates the two readings is already written into the contract: the ReConnection Phase 3 readouts and the DEA scheduling decision.

What this does and doesn't mean for you

For an LLY shareholder, be honest about proportion: roughly $2.8 billion is small against a stock trading near its two-hundred-day average around $1,000. It moves the pipeline narrative, not the near-term earnings story. For a watcher with no position, the correct box is "watchlist," with three checkable inputs that fit tonight: has VLS-01's Phase 3 started (that is a dollar a share, on a four-year clock); does BPL-003's Phase 3 data hold up; and does the DEA answer schedule it.

And the expiry clause, because every playbook has one: this read retires the day the first ReConnection study reads out or the FDA/DEA answer is known. After that, the CVR math goes binary and "psychedelic optionality" stops being a thesis and becomes a dated set of payoffs. Until then, ignore the thread lore that Lilly has gone "all in" on psychedelics — it spent a mid-size, milestone-gated sum on optionality — and track the table, because the table is the only part of this deal that talks back.